NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $31.54 +1.23 (+4.06%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$31.58 +0.04 (+0.11%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harrow alerts:Sign Up Key Stats Today's Range$30.02▼$31.6350-Day Range$22.91▼$31.6152-Week Range$16.87▼$59.23Volume350,069 shsAverage Volume499,902 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$61.40Consensus RatingBuy Company OverviewHarrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More… Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 51% of companies evaluated by MarketBeat, and ranked 1237th out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 4 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.53) to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -33.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -33.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 15.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.69% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Harrow has recently increased by 1.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.69% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Harrow has recently increased by 1.20%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment0.83 News SentimentHarrow has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Harrow this week, compared to 4 articles on an average week.Search Interest8 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Harrow to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders15.16% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Stock News HeadlinesHarrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Buy" from AnalystsJune 17 at 2:55 AM | americanbankingnews.comI Am Swimming In Dividends With +7% YieldsJune 13, 2025 | seekingalpha.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 17, 2025 | Investors Alley (Ad)Harrow (NASDAQ:HROW) Earns Buy Rating from Analysts at BTIG ResearchJune 13, 2025 | americanbankingnews.comWilliam Blair Initiates Coverage of Harrow (HROW) with Outperform RecommendationJune 12, 2025 | msn.comHarrow wins new Outperform at William Blair after licensing deal for pain drugJune 10, 2025 | msn.comHarrow acquires U.S. commercial rights to BYQLOVI from Formosa PharmaceuticalsJune 10, 2025 | msn.comHarrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa PharmaceuticalsJune 9, 2025 | prnewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $33.55 at the beginning of 2025. Since then, HROW shares have decreased by 6.0% and is now trading at $31.54. View the best growth stocks for 2025 here. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its earnings results on Thursday, May, 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by $0.40. The business had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57 million. Harrow had a negative trailing twelve-month return on equity of 45.57% and a negative net margin of 19.75%. Read the conference call transcript. Who are Harrow's major shareholders? Harrow's top institutional shareholders include Vanguard Group Inc. (5.09%), Braidwell LP (2.61%), Royce & Associates LP (0.89%) and Rice Hall James & Associates LLC (0.83%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/08/2025Today6/16/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$61.40 High Stock Price Target$65.00 Low Stock Price Target$55.00 Potential Upside/Downside+94.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.41 million Net Margins-19.75% Pretax Margin-19.67% Return on Equity-45.57% Return on Assets-8.87% Debt Debt-to-Equity Ratio3.23 Current Ratio1.55 Quick Ratio1.44 Sales & Book Value Annual Sales$212.86 million Price / Sales5.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book15.69Miscellaneous Outstanding Shares36,685,000Free Float30,746,000Market Cap$1.16 billion OptionableOptionable Beta0.40 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:HROW) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
